Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Antonio Lacquaniti, Patrizio Pasqualetti, Teresa Casuscelli di Tocco, Susanna Campo, Stefania Rovito, Maurizio Bucca, Antonino Ragusa, Paolo Monardo
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	The Korean Society of Nephrology 2020-09-01
Edice:	Kidney Research and Clinical Practice
Témata:	anemia erythropoietin resistance index ferric carboxymaltose hemodialysis
On-line přístup:	https://doi.org/10.23876/j.krcp.20.015
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!